Premium
Nucleolar organizer regions and PCNA expression in prostatic cancers
Author(s) -
Kawase Norio,
Shiokawa Akira,
Ota Hidekazu,
Saitoh Toyohiko,
Yoshida Hideki,
Kazama Kazuo
Publication year - 1994
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.1994.tb02595.x
Subject(s) - proliferating cell nuclear antigen , nucleolus organizer region , pathology , nucleolar organizer region , immunohistochemistry , nucleolus , biology , stain , lymphovascular invasion , carcinoma , anaplasia , cancer , medicine , staining , metastasis , biochemistry , cytoplasm
Argyrophilic nucleolar organizer regions (AgNOR) of 79 prostatic adenocarcinomas, and an immunohistochemical stain using a monoclonal antibody against proliferating cell nuclear antigen (PCNA) of 54 prostatic adenocarcinomas, obtained by needle biopsy and transurethral resection of the prostate between 1986 and 1989, were investigated. A morphological classification was devised to count silver dots based on the relations between intra‐ and extra‐nucleolar AgNOR (type A, B, C and D). Total AgNOR counts were significantly higher in carcinoma (4.2 ± 1.57) than in the benign prostatic lesions (1.90 ± 0.24). Count differences of AgNOR were evident in histological differentiation, nuclear anaplasia, and presence of nucleoli, mitosis, lymphatic invasion and vascular invasion. Higher total AgNOR counts were almost always associated with type B and C AgNOR (intra‐nucleolar AgNOR), but were not associated with type A (nucleolus without small dot) nor type D (extra‐nucleolar AgNOR). This study shows the diagnostic value of AgNOR in prostatic cancer, and the importance of morphological classification of AgNOR. The survival of patients with higher AgNOR counts (≧4.3) was significantly poorer than survival of those with lower AgNOR counts (< 4.3). Significantly more PCNA positive cells were identified in cancer by immunohistochemical stain and correlated with the presence of mitosis, but there was no significant difference in survival rate groups classified by PCNA positivity. It is also suggested that PCNA can be a useful marker of cell proliferation in prostatic lesions, but the AgNOR counts were diagnostically and prognosticate more valuable than immunohistochemical PCNA in prostatic lesions. The correlation between AgNOR and PCNA Immunoreactivity was not significant.